Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 4;6(1):138.
doi: 10.1186/s40425-018-0453-4.

SITC 2018 Workshop Report: Immuno-Oncology Biomarkers: State of the Art

Collaborators, Affiliations
Free PMC article

SITC 2018 Workshop Report: Immuno-Oncology Biomarkers: State of the Art

Lisa H Butterfield et al. J Immunother Cancer. .
Free PMC article


Identification of biomarkers in cancer immunotherapy that predict therapeutic response and/or limit adverse events are a critical need in the field. To address recent progress and hurdles around cancer biomarker development and utilization, the Society for Immunotherapy of Cancer (SITC) convened a workshop, "Immuno-Oncology Biomarkers: State of the Art," on May 16-17, 2018. Topics discussed included challenges in handling biospecimens, identification and validation of new biomarkers, data sharing, and collaborating across disciplines to advance biomarker development. Panel discussions followed session presentations to help foster participant conversation and discuss future projects and collaborations. The results of the Workshop include the development of new initiatives for the SITC Biomarkers Committee.

Keywords: Biomarkers; Cancer immunotherapy; Checkpoint inhibitor; PD-1/PD-L1.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

LHB serves on the advisory board for SapVax, Simpatica and Stem Immune. She has also sat in on advisory board meetings for Kite Pharma, Shire and Verastem. MLD has received royalties and has receipt of intellectual property rights from the University of Washington. She has also received research funding from EMD Sorono, Epithany, Pfizer, Janssen, Celegene, Silverback Therapeutics, and holds ownership interests in Epithany. BAF is a co-founder and has ownership in UbiVac. He also receives research support from Bristol-Myers Squibb, Janssen Biotech, Definiens/AstraZeneca, PerkinElmer, Macrogenics, OncoSec, NanoString and Shimadzu. SNK is a board member for Advaxis and Cancer Panels. He is also an advisory member for AstraZeneca, Syndax, Merus BV, IO Biotech, Navigant, Tessa Therapeutics, PDS Biotechnology, BioLine Therapeutics, NewLink Genetics, Bullet BioTech, UbiVac, CanImGuide Therapeutics, Northwest Biotherapeutics, Hikma Pharmaceuticals, CytomX Therapeutics and AratingaBio JNC. DRK did not report any conflicts of interest. EW did not report any conflicts of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

See all similar articles

Cited by 2 articles


    1. Hellmann MD, et al. Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. doi: 10.1056/NEJMoa1801946. - DOI - PubMed
    1. Davis KL, et al. ADVL1412: Initial results of a phase I/II study of nivolumab and ipilimumab in pediatric patients with relapsed/refractory solid tumors—a COG study. J Clin Oncol. 2017;35(15_suppl):10526. doi: 10.1200/JCO.2017.35.15_suppl.10526. - DOI
    1. Danilova L, et al. The mutation-associated Neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity. Cancer Immunol Res. 2018;6(8):888–899. doi: 10.1158/2326-6066.CIR-18-0129. - DOI - PMC - PubMed
    1. Chen PL, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6(8):827–837. doi: 10.1158/2159-8290.CD-15-1545. - DOI - PMC - PubMed
    1. Hodi FS, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014;312(17):1744–1753. doi: 10.1001/jama.2014.13943. - DOI - PMC - PubMed

Publication types